Navigation Links
Rigel's R788 Phase 2a Results Published in Arthritis and Rheumatism
Date:11/11/2008

officer of Rigel. Results from both studies are expected to be available in late summer 2009.

TASKi2 will evaluate RA patients receiving 100 mg of R788 orally, twice a day or 150 mg once a day, compared with those receiving placebo in a multi- center, randomized, double blind, placebo controlled parallel dose study of RA patients who have failed to respond to methotrexate. TASKi2 will enroll 420 patients (all of whom have been identified) to receive study drug or placebo, along with their steady dose of methotrexate, over a 6 month treatment period.

TASKi3 will evaluate RA patients receiving 100 mg of R788 orally, twice a day, compared with those receiving placebo in a multi-center, randomized, double blind, placebo controlled, parallel dose study of R788 in patients who have failed at least one marketed biologic agent (i.e., anti-TNF injectibles commonly used to treat RA). Approximately 195 patients are expected to be enrolled in TASKi3. Each will receive R788 or placebo over a 3 month treatment period.

For more information about the TASKi studies and R788's mechanism of action in RA and other autoimmune disorders, please visit the company's website.

About Rigel (http://www.Rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, inc
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
2. Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
3. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
4. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
5. Patient Recruitment Begins in India for Phase 3 Diabetes Trial
6. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
7. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
8. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
9. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
10. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
11. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Concord Medical Services Holdings Limited ("Concord Medical" or the ... hospital management solution provider and operator of the largest ... China , today announced that on July ... cash dividend of US$0.30 per ordinary share (or US$0.90 ... ordinary shares. The total expense for the special dividend ...
(Date:7/28/2014)... CHAPEL HILL, N.C. , July 28, 2014 /PRNewswire/ ... results of a clinical trial demonstrating that CXL-1427, a ... was well tolerated in healthy volunteers. The company has ... failure in a Phase IIa clinical trial designed to ... as its dosing levels. The Phase I ...
(Date:7/28/2014)... 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... Financial Results and Highlights Conference CallWhen:Monday, August 4 at ... How:Live on the Internet. Simply log onto our website ... the live event, a replay of the webcast will ... . ABOUT ISIS PHARMACEUTICALS, INC. Isis is ...
Breaking Medicine Technology:Concord Medical Declares Special Dividend 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2
... allergic,asthma attacks and further define Xolair safety profile in ... up to their 12th birthday, - Xolair is ... associated,with approximately 78% of childhood asthma, - Allergic ... the age,of 18, - Xolair is currently approved ...
... SPEX ) reported that patient recruitment for its ... drug, Naturlose(R), has begun in,India. Expectations for India are ... for the pivotal Phase 3 trial. "Now that enrollment ... 3 trial will be completed,on schedule as reported during ...
Cached Medicine Technology:Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids 2Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids 3Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids 4Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids 5Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids 6Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids 7Patient Recruitment Begins in India for Phase 3 Diabetes Trial 2
(Date:7/28/2014)... 28, 2014 Glutamine is the most ... considered to be conditionally essential during times when the ... advanced recovery & Immune System Support. , Having a ... body produces, supplementing with additional glutamine may be advantageous. ... in the body, digestion and immune system function. Stress ...
(Date:7/28/2014)... By Maureen Salamon ... (HealthDay News) -- Infants and children who are at ... should be vaccinated against the infection, according to updated ... States. And routine vaccinations for the potentially ... the American Academy of Pediatrics says. In its ...
(Date:7/28/2014)... Endurance runners are far more likely to die of ... a new study. The researchers pointed out ... are actually 10 times more likely to develop severe ... death of a young and apparently healthy person due ... often gets a lot more media attention. "This ...
(Date:7/28/2014)... 28, 2014 SIMpalm helped its ... App is available on iTunes for download . Experience ... Audio Chef allows you to listen and cook along with ... way: simply get out the ingredients and equipment, press play, ... or prepare ingredients ahead of time, just relax and cook ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 The ... that has donated more than 200,000 books to children ... announces the launch of Brooke’s Cooks, a new initiative ... encouraging healthy living among at-risk children and their families ... include a series of nutrition information workshops, cooking demonstrations ...
Breaking Medicine News(10 mins):Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 2Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 3Health News:Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: Study 2Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 2Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 4Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 2Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 4
... women receiving the same breast cancer treatments as Hispanic ... lower survival rates, were more likely to be diagnosed// ... to a study. ,For the study, ... M. D. Anderson Cancer Center and colleagues examined 2,140 ...
... According to a recent analysis by Metropolitan Transportation Authority, ... excessive dieting are among the top// causes, after the ... US subway. ,Asim Nelson, a transit ... statistics, taken between October 2005 and October 2006, shows ...
... among states and union territories to enforce screening of all ... disorder// that could lead to disabilities. ,Chandigarh ... children would be done to check any adverse fallout later. ... ,While poor people would be provided the facility ...
... giant-Coco Cola and Nestle have come together to manufacture a ... tea, caffeine and plant micronutrients. This is expected to hit ... consumers shed excess weight. ,According the chief scientist ... calories burnt. The soft drink company claims that detailed studies ...
... proposal released by Gov. Arnold Schwarzenegger recently, workers in ... benefit - to their// health and wealth. Employees will ... exempted from tax. ,The proposal is an ... reachable to the approximate 6.5 million Californians who are ...
... make you diabetic, says a study that tracked hospitalisation rates ... ,Type-two diabetes has seen a two-fold increase - from ... While scientists scramble to find explanations for the rise, experts ... , ,However, the study by Lawrence Lessner and colleagues ...
Cached Medicine News:Health News:Living Near Toxic Waste May Bring On Diabetes 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: